# Wastewater Surveillance of SARS-CoV-2 across 40 U.S. states

Fuqing Wu(1,2)†; Amy Xiao(1,2)†; Jianbo Zhang(1,2); Katya Moniz(1,2); Noriko
Endo(3); Federica Armas(4,5); Mary Bushman(6); Peter R Chai(7,8); Claire
Duvallet(3); Timothy B Erickson(7,9,10); Katelyn Foppe(3); Newsha Ghaeli(3);
Xiaoqiong Gu(4,5); William P Hanage(6); Katherine H Huang(11); Wei Lin
Lee(4,5); Mariana Matus(3); Kyle A McElroy(3); Steven F Rhode(12); Stefan
Wuertz (5,13,14); Janelle Thompson(5,13,15); Eric J Alm(1,2,4,5,11)*

1: Department of Biological Engineering, Massachusetts Institute of Technology
2: Center for Microbiome Informatics and Therapeutics, Massachusetts Institute
of Technology
3: Biobot Analytics, Inc., Cambridge, MA
4: Singapore-MIT Alliance for Research and Technology, Antimicrobial
Resistance Interdisciplinary Research Group, Singapore
5: Campus for Research Excellence and Technological Enterprise (CREATE),
Singapore
6: Harvard T.H. Chan School of Public Health, Harvard University
7: Division of Medical Toxicology, Department of Emergency Medicine, Brigham
and Women's Hospital, Harvard Medical School
8: The Fenway Institute, Fenway Health, Boston, MA
9: The Koch Institute for Integrated Cancer Research, Massachusetts Institute of
Technology
10: Harvard Humanitarian Initiative, Harvard University
11: Broad Institute of MIT and Harvard, Cambridge, MA, USA
12: Massachusetts Water Resources Authority, Boston, MA
13: Singapore Centre for Environmental Life Sciences Engineering, Nanyang
Technological University, Singapore
14: Civil and Environmental Engineering, Nanyang Technological University,
Singapore
15: Asian School of the Environment, Nanyang Technological University,
Singapore

† These authors contributed equally.
* Correspondence to EJA at ejalm@mit.edu

**Abstract**

Wastewater-based disease surveillance is a promising approach for monitoring community outbreaks. Here we describe a nationwide campaign to monitor SARS-CoV-2 in the wastewater of 159 counties in 40 U.S. states, covering 13% of the U.S. population from February 18 to June 2, 2020. Out of 1,751 total samples analyzed, 846 samples were positive for SARS-CoV-2 RNA, with overall viral concentrations declining from April to May. Wastewater viral titers were consistent with, and appeared to precede, clinical COVID-19 surveillance indicators, including daily new cases. Wastewater surveillance had a high detection rate (>80%) of SARS-CoV-2 when the daily incidence exceeded 13 per 100,000 people. Detection rates were positively associated with wastewater treatment plant catchment size. To our knowledge, this work represents the largest-scale wastewater-based SARS-CoV-2 monitoring campaign to date, encompassing a wide diversity of wastewater treatment facilities and geographic locations. Our findings demonstrate that a national wastewater-based approach to disease surveillance may be feasible and effective.

**Introduction**

COVID-19 was first reported in the United States on January 20, 2020, and spread to all 50 states and the District of Columbia by mid-March[1,2]. As of February 1, 2021, over 26 million confirmed cases and over 440,000 deaths have been reported in the U.S.[2]. Establishing a national COVID-19 surveillance system, like those for viral hepatitis and influenza, would be helpful for long-term monitoring of SARS-CoV-2, allowing healthcare officials to recognize and respond to new outbreaks efficiently and uniformly. However, COVID-19 poses specific challenges to clinical surveillance systems, with its long infectious incubation time (up to 14 days; median: 4-5 days) greatly increasing the risk of viral transmission and infection among the population before clinical reporting, contact tracing, and containment can occur[3,4]. "Test and trace" systems were rapidly overwhelmed in many countries early in the pandemic, and are often ineffective once a disease reaches exponential community spread[5,6]. The emergence of more infectious variants may exacerbate this problem[7,8].

As a complementary approach to clinical disease surveillance, wastewater monitoring can help detect the presence of pathogens like the coronavirus SARS-CoV-2 across municipalities, and estimate disease incidence independent of individual testing[9–11]. Wastewater surveillance is less resource intensive than large-scale clinical testing, making it an optimal tool for unobtrusive, long-term monitoring as well as early identification of viral circulation in the population. Our recent findings[9,10] along with work from other groups have described reliable detection of SARS-CoV-2 gene fragments in wastewater samples across the world, including Australia[12], Brazil[13], France, Netherlands[14], Italy[15], Spain[16], and the U.S.[9,17]. Furthermore, longitudinal wastewater viral titers correlate with clinically diagnosed new COVID-19 cases, and trends in wastewater precede those in clinical reports by 4-10 days, suggesting that wastewater data could be used as an early warning of impending outbreaks to define public health and hospital planning[10]. The potential value of wastewater surveillance is gaining recognition, with the Centers for Disease Control and Prevention and several state and local health agencies initiating wastewater-based monitoring programs to supplement their COVID-19 responses[18].

We implemented a nationwide COVID-19 surveillance campaign to measure viral concentrations of SARS-CoV-2 in the wastewater of 159 counties in 40 U.S.

states, from February to June 2020. We investigated the detection rate and
accuracy of wastewater surveillance of SARS-CoV-2 by comparing wastewater
data to clinically reported case counts from state and local health agencies. We
demonstrated the feasibility of utilizing wastewater surveillance as a supplement
to national SARS-CoV-2 clinical reporting data to understand important past,
current and future trends in viral dynamics.
115
116
117    **Results**
118
We collected and processed 1,751 wastewater samples from 353 unique
locations in 159 counties, in 40 U.S. states, from February 18 to June 2, 2020
(Fig. 1A). Of these samples, 1,687 were from locations that authorized the
disclosure of their metadata. Individual samples represented catchments serving
population sizes ranging from 65 to 5.3 million sewered individuals, with a
median size of 31,745 people (Fig. S1a). In total, these wastewater samples
covered 42.5 million people – approximately 13% of the U.S. population. To our
knowledge, this is the largest dataset reporting temporal tracking of SARS-CoV-2
in wastewater. Samples were processed as they were received in the lab and
quantified by real-time quantitative PCR (see Methods). 830 samples (49.1%)
were positive for SARS-CoV-2 gene fragments.
130
**Temporal dynamics of SARS-CoV-2 titers in wastewater samples from 159**
**counties in 40 states.**
For the month of March, we analyzed 86 wastewater samples from 25 counties
(42 individual catchments), in 10 states. We observed significant heterogeneity in
results at the county level. 44 of the 86 samples (51%) (from 12 counties in 8
states) were positive for SARS-CoV-2. In California, we found only 3 positive
samples from the 14 sampling locations (21%) in the 7 counties sampled in
March. On the other hand, we consistently detected SARS-CoV-2 in a
Massachusetts wastewater treatment plant (WWTP) starting on March 3 (93% of
samples), with viral titers increasing throughout the month (Fig. 1a). Positive
samples were also found in more than two counties in Colorado, Oregon, and
Texas.
143
In April, viral titers stopped increasing and became relatively stable for most
sampling locations (Fig. 1a and Fig. S1). Of the samples tested in April, 52.9%

(255 of 482) were SARS-CoV-2 positive: 173 samples from 44 counties had viral
titers between 10-100 copies per ml of wastewater; 78 samples from 24 counties
had viral titers higher than 100 copies per ml (Fig. 1a). We processed 1,092
samples from 154 counties in May. Of these, 69.5% (358/515) had positive
SARS-CoV-2 titers of 10-100 copies per ml of wastewater, and 18.8% (97/515)
had titers of >100 copies per ml (Fig. 1a). Analysis of April and May samples also
showed the heterogeneity in viral titers at the county and catchment levels (Fig.
S2).
154
We observed different dynamics in viral titers at the state level (Fig. 1a). Viral
titers in New Jersey (NJ) were high in March samples, but started to decrease
after April 8. Similar temporal dynamics were also observed in Michigan (MI), but
with a smaller magnitude. Comparatively, viral titers in Indiana (IN) and North
Carolina (NC) varied little over the sampling period (April and May). Nine states
(Virginia, Delaware, Michigan, Minnesota, Massachusetts, Oregon, New York,
Nebraska, and New Jersey) had titers higher than 100 copies per ml of
wastewater in April (Fig. 1b). This number dropped to two states (Maryland and
Minnesota) in May (Fig. 1c). Averaged across all states, the mean viral
concentration was significantly higher in April than in May (Fig. S1b). Together,
these data highlight that wastewater surveillance can be implemented to explore
viral transmission at different geographic and temporal scales.
167

**Wastewater viral dynamics are consistent with clinical COVID-19**
**surveillance indicators**
Next, we compared the wastewater viral titers with clinical surveillance data of
COVID-19 across the U.S. Aggregating the positive wastewater data and daily
new COVID-19 cases and new deaths by date, the mean viral titers increased
from early March and became relatively stable between late March to late April,
followed by a small downward trend until June 2 (Fig. 1d). This temporal profile
mirrors the trends of clinical new cases and deaths at the national level, and
precedes clinical data. Wastewater viral titers also reflected, and seemed to
precede, the rise and fall of hospitalization and intensive care unit admissions
(Fig. S3).
179

We also investigated the relationship between wastewater viral titers and daily
COVID-19 incidence rates. Viral concentration in the wastewater is determined
by the number of new infections, shedding rates from infected individuals, as well

as total influent flow at the wastewater treatment plant[10], which is linearly
correlated with catchment population size (Fig. S4). A weak positive correlation
was found between the incidence of daily new cases at the county level, and the
wastewater viral titers at the catchment (wastewater treatment plant) level (Fig.
1e). We then compared total daily viral load for each catchment (viral
concentrations detected at wastewater treatment plant, multiplied by the plant's
daily influent flow rate), and the estimated number of new cases in that
catchment (county-level incidence rates multiplied by the catchment population).
A linear relationship was observed between the total viral load and catchment
size-normalized daily new cases (Fig. 1f), consistent with the hypothesis that
average shedding rates are similar across catchments.
194
**Estimation of detection rate and accuracy of wastewater surveillance**
Next, we investigated the detection rate of wastewater surveillance by comparing
wastewater titers to new clinical cases on the sampling day (Methods). Using the
reported daily incidence COVID-19 cases (i.e. daily new cases divided by the
county population size), we calculated the percentage of positive wastewater
samples for different incidence rates. Wastewater-based detections increased
exponentially with the clinical incidence rate, reaching an 80% rate of detection at
a clinical incidence of 13 cases per 100,000 people (Fig. 2a). For all positive
wastewater samples at the county level, the associated incidence rates of daily
new cases ranged from 0 – 149.6 cases per 100,000 people (median: 3.7 cases
per 100,000 people) (Fig. 2b). In other words, wastewater-based surveillance
was capable of detecting SARS-CoV-2 for one new reported case out of ~27,000
people. However, this new case rate does not consider unreported infections in
the population, which would lower the estimated detection limit.
209
To evaluate whether catchment size influences the probability of SARS-CoV-2
detection in wastewater samples, we analyzed the detection rate of positive
samples from counties with equal daily incidence. As shown in Fig. 2c, detection
rate is positively associated with the population size of wastewater treatment
plant catchments for the majority of samples. 100% detection rates were
disproportionately represented among samples with high incidence (>10 cases
per 100,000 people) and large population sizes (>100,000 people). This result is
consistent with our previous model simulations that the probability of SARS-CoV-
2 detection in the wastewater increases with population size in communities with
equal incidence[10].

To evaluate the detection accuracy of wastewater surveillance, we compared the

wastewater results with reported daily new clinical cases. For all 1,687 samples

for which we had access to metadata, 1,057 (62.7%) exhibited results consistent

with the geographically associated clinical data, meaning that SARS-CoV-2 was

detected in the wastewater in areas with new clinical cases (759 samples,

"W1.C1"), and not detected in areas where no new cases were reported (298

samples, "W0.C0") (Fig. 2d). Of the remaining 630 samples, 559 had clinical

cases but SARS-CoV-2 was not detected in the wastewater ("W0.C1"). Of these,

67.4% were from counties with incidence rates below the median of all

wastewater samples (3.7 cases per 100,000). We also compared the pepper

mild mottle virus levels (PMMoV), a stable and persistent indicator of fecal

concentration in wastewater[9,19,20], and found that PMMoV copies in the W0.C1

samples were slightly but significantly lower than in other samples (Fig. S5a),

suggesting that sample dilution and low incidence rates may have contributed to

wastewater non-detections. Finally, there were 71 samples ("W1.C0") for which

SARS-CoV-2 was detected, but there were no new clinical cases reported (Fig.

2d). Most of these samples' viral titers ranged from 10 to 272 copies/ml (Fig.

S5b). Comparison of the wastewater data against the 7-day averages of new

clinical cases did not yield substantially different results (Fig. S5c-d).

**Discussion**

In this study, we tested and quantified SARS-CoV-2 genome copies in 1,751

wastewater samples, collected from 159 U.S. counties in 40 states, using RT-

qPCR. This nationwide campaign covered approximately 13% of the U.S.

population and demonstrated that widespread wastewater surveillance is feasible

and useful across various catchment sizes. Overall, viral titers increased starting

in early March, and became relatively stable until April, followed by a small

decrease in May. Thirty-eight out of 40 states we sampled issued stay-at-home

orders or advisories between March 19 and April 7, and all 40 sampled states put

statewide restrictions on activity in place between March 10 and April 6

(https://www.usatoday.com/storytelling/coronavirus-reopening-america-map/).

These social distancing guidelines may have contributed to the relatively stable

viral titers in April and downward trend in May.

Wastewater surveillance of SARS-CoV-2 has been widely employed in the U.S.
and other countries, however, the detection rate and limit have been unclear. Our
spatiotemporal wastewater dataset enabled us to address this question.
Assuming an equal incidence rate throughout the county, our analysis showed
that wastewater-based SARS-CoV-2 monitoring has a high chance (> 80%) of
detecting the viral RNA when the incidence of daily new cases exceeds 13 cases
per 100,000 people. Considering only positive wastewater samples, the median
detection limit becomes 1 case per ~27,000 people. Our analysis is based on
case reports from public health agencies, which are likely underestimates of true
infection rates.
267
This study has several limitations. First, all surveillance data are limited by
sampling regimes which could introduce bias through either the frequency of
sampling or the specific locations sampled, which is true for both wastewater
surveillance and case counts reported by public health authorities. A more
unbiased sampling strategy including representative locations and appropriate
time intervals would improve our estimate about the viral transmission in the
population. Second, sample numbers were biased by month, 5.1% samples were
from March and 55.5% samples were from May, thus our analysis may be
affected by the low sampling resolution during the early stage of the pandemic.
Third, all the samples were collected by each wastewater treatment plant, and
mailed to us for analysis, and thus variation in sample collection and transport
conditions may have further influenced data comparability. National
implementation of a wastewater-based detection system would require standard
operating procedures for sample collection, local processing, and analysis.
282
Here, we reported wastewater levels of SARS-CoV-2 in 159 counties in 40 U.S.
states, from mid-February to early June 2020, and showed that wastewater data
largely parallels and precedes clinical and epidemiological indicators of COVID-
19 pandemics. Across the country, wastewater surveillance had a high SARS-
CoV-2 detection rate (>80%) when the local daily incidence exceeded 13
reported cases per 100,000 people. The detection rate was positively associated
with catchment population size. To our knowledge, this is the largest nationwide
investigation of SARS-CoV-2 in wastewater samples in the U.S. during the
COVID-19 pandemic, with samples from 353 catchments representing 13% of
the U.S. population. This noninvasive and cost-effective approach could be
employed as a complementary tool for long-term monitoring of SARS-CoV-2 - as

well as other infectious diseases and other health-relevant biomarkers - across
the United States.
296
297
298  **Methods**
299
**Sample collection and viral inactivation.** We initiated a national call for
wastewater samples to quantify SARS-CoV-2 viral load in wastewater catchment
areas from mid-February to early June 2020. Eligible sites included public works
and wastewater authorities across the continental United States. Samples were
collected by each wastewater treatment facility on a voluntary basis. Raw
wastewater samples were collected from the wastewater treatment plants or
catchments in 40 U.S. states and stored at 4C before being mailed to the
laboratory for analysis. Samples were processed using the method as previously
described[9,10]. Briefly, samples were first inactivated by ultraviolet light for 20 mins
and heat treatment in a 60C water bath for 90 mins. Pasteurized samples were
vacuum filtered with a 0.22-um polyethersulfone membrane to remove cell debris
and solid materials. Supernatant was stored at 4C, and used for the viral
enrichment.
313
**Viral precipitation, RNA extraction, reverse transcription and quantitative**
**PCR (RT-qPCR).** We processed the samples starting from viral enrichment to
quantitative PCR with two comparable methods as previously described[10]. 60
samples from deer island wastewater treatment plant were processed with both
two methods, and no significant difference between viral titers was observed[10].
1023 samples were processed with Method I, and 729 samples were processed
with Method II. Briefly, viral particles in 40-ml filtrate were precipitated with
polyethylene glycol 8000 (10% w/v, Millipore sigma) and NaCl (0.3M, Millipore
sigma) in Method I. Viral pellet was resuspended in 1.5 mL Trizol reagent (Cat#
15596026, Thermo Fisher Scientific) for RNA extraction. cDNA was synthesized
by reverse transcription (RT) based on the manufacturer's protocol (M0368, New
England Biosciences), followed by real-time PCR with the TaqMan® Fast
Advanced Master Mix and U.S. CDC N1, N2 primer/probes. The qPCR reaction
was carried out for 48 cycles using Bio-Rad CFX96 Real-Time PCR Detection
System with following program: polymerase activation (95°C for 2 min), PCR (48
cycles, denature at 95°C for 1 s, and anneal/extend at 55°C for 30 s).
330

15 ml of filtrate in Method II were first concentrated with 10 kDa Amicon Ultra
Centrifugal Filter (Sigma, Cat# UFC9010) to 150 ~ 200 ul, which is further lysed
with 600 ul AVL buffer (Qiagen, Cat# 19073) for RNA extraction (Qiagen RNeasy
kit, Cat# 74182). The eluted RNA was used for one-step RT-PCR with TaqMan™
Fast Virus 1-Step Master Mix (Thermofisher, Cat# 4444436), based on the
following protocol: 50°C 10 mins for reverse transcription, 95°C 20 s for RT
inactivation and initial denaturation, and 48 cycles of denature (95°C 1 s) and
anneal/extend (55°C 30 s).
339
Ct values for N1 or N2 primer sets were first converted to viral gene copies in the
cDNA sample (copies per ul of cDNA) based on the standard curves established
with the positive control plasmid (Method I) or Twist SARS-CoV-2 RNA (Method
II) (10). The concentration was further converted to viral gene copies per
microliter of the wastewater sample by multiplying the dilution factor. For Method
I, the dilution factor is: the volume of total cDNA * the total volume of RNA / (the
volume of RNA used for reverse transcription * the starting volume of filtered
wastewater sample). For Method II, the dilution factor is: The total volume of
RNA / the starting volume of filtered wastewater sample). Two or three replicates
were performed for each primer set, averaged within each primer set and then
across primers to derive the concentration values. We also measured PMMoV
concentration in the sample as an internal reference for wastewater samples. We
performed two technical replicates for each sample and converted the mean Ct
values to relative concentrations of viral particles based on the standard curve[9]
and sample's dilution factor.
355
**Clinical data collection and detection rate analysis.** County-level clinical data
including cumulative COVID-19 cases and deaths were downloaded from
USAFACTS (https://usafacts.org/visualizations/coronavirus-covid-19-spread-
map/). Daily new cases or deaths were generated through using the cumulative
data on one day to subtract the data before that day. We compared wastewater
viral titers to clinical data reported for the day on which the sample was obtained.
For the detection accuracy analysis in Fig. S5c-d, we also compared the
wastewater data against the 7-day moving average of new clinical cases (current
day + 6 preceding days / 7). Hospitalizations and positive rates of testing for each
state were downloaded from The COVID Tracking Project
(https://covidtracking.com/).
367

Incidence rate of daily new cases was calculated using reported daily new cases
in the county divided by the county population size. In Fig. 2a, we computed the
detection rates, percentage of positive wastewater samples, for a constant
interval (0.2 cases per 100,000 people) of daily incidence, starting from 0 to
149.6 cases per 100,000 people (maximum daily incidence). The results were
fitted using an exponential decay function with formula: y ~ $k_1$ + $V_{max}$ * ($k_2$ - exp(-x
/ $tau$), starting from $V_{max}$ = 10, tau = 1, and $k_1$ = 0.2, $k_2$ = 1.15. To estimate the
distribution of daily incidence for all the positive samples, we first aggregated
wastewater viral titers for each county, since clinical cases were reported at the
county level. Then we selected the positive samples and plotted the histogram
and Kernel density estimation of the distribution of daily incidence (Fig. 2b). In
Fig. 2c, we investigated the relationship between detection rate of positive
wastewater samples and the catchment population size. We first separated the
samples based on four different daily incidences (0, (0,2), [2,10), and [10,100),
per 100,000 people) in the county where the sample was obtained. For each
daily incidence, we computed the detection rate for a constant interval of
population size, i.e. the maximum minus minimum of population size, and divided
by the number of bins (n=200). All the analysis was done with R (3.5.0).
386
387

**Acknowledgments**
We thank the management and sampling teams at all the wastewater treatment
facilities who worked with us in providing the samples for analysis. We thank
Penny Chisholm (MIT) and Allison Coe (MIT) for access to equipment and other
supplies, Shandrina Burns (MIT) for logistical support. Finally, we express our
deep gratitude to all healthcare professionals and first-line responders who have
been caring for patients with COVID-19.
395
This work was supported by the Center for Microbiome Informatics and
Therapeutics and Intra-CREATE Thematic Grant (Cities) grant NRF2019-
THE001-0003a to JT and EJA; National Institute on Drug Abuse of the National
Institutes of Health award numbers K23DA044874; and R44DA051106 to MM
and PRC, Hans and Mavis Psychosocial Foundation funding, and e-ink
corporation funding to PRC; funding from the Morris-Singer Foundation and NIH
award R01AI106786 to WPH; funds from the Massachusetts Consortium on
Pathogen Readiness and China Evergrande Group to TBE, PRC, MM, and EJA;
funding from the Singapore Ministry of Education and National Research

Foundation through an RCE award to Singapore Centre for Environmental Life
Sciences Engineering (SCELSE) to SW and JT. The content is solely the
responsibility of the authors and does not necessarily represent the official views
of the funding institutions.
409
410

411 **Competing Interests**
412 MM and NG are cofounders of Biobot Analytics. EJA is advisor to Biobot
413 Analytics. CD, KAM, KF, and NE are employees at Biobot Analytics, and all
414 these authors hold shares in the company.
415
416

417 **Data Availability**
418 The data presented in the figures, and the code for the analysis, and that support
419 the other findings of this study are available from the corresponding author on
420 reasonable request.
421
422

**References**
1. Holshue, M. L. *et al.* First Case of 2019 Novel Coronavirus in the United
States. *New England Journal of Medicine* **382**, 929–936 (2020).
2. Johns Hopkins University Center for Systems Science and Engineering.
COVID-19 Map - Johns Hopkins Coronavirus Resource Center.
https://coronavirus.jhu.edu/map.html (2020).
3. Lauer, S. A. *et al.* The Incubation Period of Coronavirus Disease 2019
(COVID-19) From Publicly Reported Confirmed Cases: Estimation and
Application. *Ann Intern Med* (2020) doi:10.7326/M20-0504.
4. CDC. Coronavirus Disease 2019 (COVID-19)-COVID-19 Pandemic Planning
Scenarios. *Centers for Disease Control and Prevention*
https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html
(2020).
5. Kretzschmar, M. E. *et al.* Impact of delays on effectiveness of contact tracing
strategies for COVID-19: a modelling study. *The Lancet Public Health* **5**,
e452–e459 (2020).

6. Contreras, S. *et al.* The challenges of containing SARS-CoV-2 via test-trace-
and-isolate. *Nature Communications* **12**, 378 (2021).

7. Grubaugh, N. D., Hodcroft, E. B., Fauver, J. R., Phelan, A. L. & Cevik, M.
Public health actions to control new SARS-CoV-2 variants. *Cell* (2021)
doi:10.1016/j.cell.2021.01.044.

8. Galloway, S. E. Emergence of SARS-CoV-2 B.1.1.7 Lineage — United
States, December 29, 2020–January 12, 2021. *MMWR Morb Mortal Wkly*
*Rep* **70**, (2021).

9. Wu, F. *et al.* SARS-CoV-2 titers in wastewater are higher than expected from
clinically confirmed cases. *mSystems* **5**, 2020.04.05.20051540 (2020).

10. Wu, F. *et al.* SARS-CoV-2 titers in wastewater foreshadow dynamics and
clinical presentation of new COVID-19 cases. *medRxiv* (2020)
doi:10.1101/2020.06.15.20117747.

11. Orive, G., Lertxundi, U. & Barcelo, D. Early SARS-CoV-2 outbreak detection
by sewage-based epidemiology. *Science of The Total Environment* **732**,
139298 (2020).

12. Ahmed, W. *et al.* First confirmed detection of SARS-CoV-2 in untreated
wastewater in Australia: A proof of concept for the wastewater surveillance of
COVID-19 in the community. *Science of The Total Environment* **728**, 138764
(2020).

13. Prado, T. *et al.* Preliminary results of SARS-CoV-2 detection in sewerage
system in Niterói municipality, Rio de Janeiro, Brazil. *Mem Inst Oswaldo Cruz*
**115**, (2020).

14. Medema, G., Heijnen, L., Elsinga, G., Italiaander, R. & Brouwer, A. Presence
of SARS-Coronavirus-2 RNA in Sewage and Correlation with Reported
COVID-19 Prevalence in the Early Stage of the Epidemic in The Netherlands.
*Environ. Sci. Technol. Lett.* (2020) doi:10.1021/acs.estlett.0c00357.

15. La Rosa, G. *et al.* First detection of SARS-CoV-2 in untreated wastewaters in
Italy. *Science of The Total Environment* **736**, 139652 (2020).

16. Chavarria-Miró, G. *et al.* Sentinel surveillance of SARS-CoV-2 in wastewater

anticipates the occurrence of COVID-19 cases. *medRxiv*

2020.06.13.20129627 (2020) doi:10.1101/2020.06.13.20129627.

17. Peccia, J. *et al.* Measurement of SARS-CoV-2 RNA in wastewater tracks

community infection dynamics. *Nature Biotechnology* 1–4 (2020)

doi:10.1038/s41587-020-0684-z.

18. CDC. National Wastewater Surveillance System. *Centers for Disease Control*

*and Prevention* https://www.cdc.gov/coronavirus/2019-ncov/cases-

updates/wastewater-surveillance.html (2020).

19. Kitajima, M., Sassi, H. P. & Torrey, J. R. Pepper mild mottle virus as a water

quality indicator. *npj Clean Water* **1**, 1–9 (2018).

20. Kitajima, M., Iker, B. C., Pepper, I. L. & Gerba, C. P. Relative abundance and

treatment reduction of viruses during wastewater treatment processes —

Identification of potential viral indicators. *Science of The Total Environment*

**488–489**, 290–296 (2014).

**Fig. 1. SARS-CoV-2 RNA gene copies in wastewater samples from 40 U.S. states.** (a) Temporal profile of SARS-CoV-2 viral RNA gene copies (viral titers) in the wastewater samples collected from February 18 to June 2, 2020. Each grey point represents a sample, and the grey line connects samples collected from the

same catchment. Temporal dynamics of mean viral titers from five U.S. states

are highlighted. Negative samples (SARS-CoV-2 not detected) were assigned to

'0'. (b-c) Mean viral titers for each state in April (b) and May (c). All the samples

in April or May were aggregated by state. NA: data is not available for the state.

(d) Temporal dynamics for the mean viral titers, daily new COVID-19 cases, and

new deaths. Viral concentrations (red line) from positive wastewater samples

were aggregated by date, and new cases (green line) and COVID-19-related new

deaths (blue line) from the wastewater sample originated counties were also

aggregated and averaged by date. (e) Association between viral titers in

wastewater samples and the reported daily incidence rate in each sampled

counties. (f) Association between the total viral load and estimated new cases in

each of the catchment areas. Total viral load of SARS-CoV-2 in wastewater

(copies/day) was calculated by multiplying SARS-CoV-2 concentration

(copies/ml) by the daily average influent flow (ml/day) reported by the WWTP.

Population weighted new cases was calculated as county new cases * catchment

population / county population.

**Fig. 2. Detection rate and accuracy of wastewater-based SARS-CoV-2 surveillance.** (a) Detection rate for varying daily incidence of COVID-19 cases. Each dot represents the percentage of positive wastewater samples for a constant incidence interval, and the red line is the nonlinear fit. The vertical dashed line indicates the incidence (x = 13) above which the fitted detection rate exceeds 0.8. (b) The distribution of daily incidence for the counties where SARS-CoV-2 was detected in the wastewater samples. Blue line is the Kernel density estimation of the daily incidence's distribution. The median of the incidence is 3.7 cases per 100,000 people). (c) Relationship between the detection rate of positive wastewater samples from a given treatment plant and the population size served by that plant. Detection rate is binned by population size, and colored by the incidence intervals. (d) Detection status for all the samples (n = 1,687).

Wx.Cx (x = 1 or 0): consistent results between wastewater data and clinical
reports. W1.C1: SARS-CoV-2 detected in Wastewater (W1) and new Clinical
cases reported (C1); W0.C0: no Wastewater detection (W0) and no new Clinical
cases reported (C0); W0.C1: no Wastewater detection (W0) but new Clinical
cases reported (C1); W1.C0: Wastewater detection (W1) but no new Clinical
cases reported (C0).

540 **Supplemental figures**

**Fig. S1.** Distribution of the wastewater treatment plant serving population size,
and viral titers in positive wastewater samples by month. (a) Histogram of
population sizes served by the sampled wastewater treatment plants. The
median served population size is 31,745. (b) Viral titers in positive wastewater
samples by month. The box represents the interquartile range of viral titers for
each month, the horizontal line inside the box is the median. Significant
difference was found between the mean viral titers in April and May (Welch's t-
test, p-value = 0.025).

a

b

**Fig. S2.** Temporal SARS-CoV-2 titers at the county level and catchment level. (a)
Temporal viral titers in 12 representative counties. Each dot is a sample, and
colored by the sampling catchments in the county. Red lines represent the daily
new cases in the corresponding counties during the sampling period. (b)
Temporal viral titers for samples collected in six different locations in the New
Castle County of Delaware. Red lines represent the weighted daily new cases
(daily new cases in the county multiplying the catchment served population size
and divided by the county population size) during the sampling period.

580
**Fig. S3.** Wastewater viral titers (top) and clinical COVID-19 surveillance
indicators including hospitalization and intensive care unit admissions (middle),
and the testing positive rates (bottom) from February to June. Positive
wastewater data from all the sampling locations were aggregated by date using
the mean function. Clinical data from the 40 sampled states were aggregated in
the same way.
587
588
589

590
591
592 **Fig. S4.** Daily average influent flow at the wastewater treatment plant is
593 correlated with catchment population size.
594
595
596

**Fig. S5.** PMMoV concentrations in wastewater samples, and detection status
with 7-day averages of new COVID-19 cases. (a) PMMoV concentrations in the
Wx.Cx (x = 0 or 1), W0.C1, and W1.C0 groups. W1.C1: SARS-CoV-2 detected in
Wastewater and new Clinical cases reported; W0.C0: no Wastewater detection
and no new Clinical cases reported; W0.C1: no Wastewater detection but new
Clinical cases reported; W1.C0: Wastewater detection but no new Clinical cases
reported. Significant differences of PMMoV concentrations were found between
W0.C1 and Wx.Cx or W1.C0 groups (Welch's t-test, and symbol *: p-value <
0.05; ***: p-value < 0.001). (b) Viral titers and the served population size for the
W1.C0 samples. Most of these samples were from catchments serving 10,000 ~
100,000 population, with viral titers ranging from 10 to 100 copies per ml of
wastewater. (c-d) Detection status for wastewater data against 7-day averages of
new clinical cases (c), and PMMoV concentrations in the Wx.Cx, W0.C1, and
W1.C0 groups (d). Significant difference was found between Wx.Cx and W0.C1
groups (Welch's t-test, and symbol ***: p-value < 0.001).